Lexicon Pharmaceuticals | LXRX - Current Assets


Lexicon Pharmaceuticals reported $186.03M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Akebia Therapeutics USD 229.55M 13.93M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Halozyme Therapeutics USD 933.02M 70.01M Jun/2026
Illumina USD 2.83B 96M Jun/2026
Insmed USD 1.63B 20.75M Jun/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
J&J USD 59.77B 601M Jun/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
MannKind USD 245.71M 5.45M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Moderna USD 5.82B 45M Jun/2026
Novartis USD 27.35B 744M Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Thermo Fisher Scientific USD 23.36B 1.05B Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
United Therapeutics USD 3.48B 611.7M Jun/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025